多西他赛周疗法治疗老年晚期非小细胞肺癌的临床观察

目的：观察多西他赛单药每周方案治疗老年晚期非小细胞肺癌（NSCLC）的临床疗效及毒副反应。方法：国产多西他赛35mg／m^2静脉滴注1小时，第1、8、15天，28天为1个周期，治疗65岁以上NSCLC患者并评价疗效及毒副反应。结果：28例患者共化疗86个周期，总有效率（CR＋PR）为35．7％（10／28），临床受益率（CR＋PR＋NC）为64．3％（18／28）。经治疗后患者KPS平均分从基线时的75．5上升至87．7（P〈0．01），咳嗽、咯血、胸痛和气促LCSS平均分从治疗前的64、65、62和65分上升至90、92、87和88分（P〈0．01）。肿瘤中位疾病进展时间为5．3个月，中位生存期为8．5个月。主要毒副作用为疲劳和骨髓抑制，但均可耐受。 结论：多西他赛周疗法治疗老年NSCLC有较好的疗效，并能有效改善症状，且患者耐受性较好。

Clinical observation of weekly dose doctaxale in the treatment of elderly patients with non-small cell lung cancer

Objective:To investigate the clinical efficacy and toxicity of elderly patients with advanced NSCLC treated with weekly dose doctaxale.Methods:Twenty-eight patients aged over 65 with advanced NSCLC were treated with doctaxale 35mg/m2 on days 1,8 and 15.The schedules were repeated every 28 days.A clinical observation on effectiveness,quality of life and toxicities was performed and analysed.Results:Twenty-eight patients were given 86 cycles' chemotherapy.The overall response rate was 35.7%(10/28).The clinical beneficial response rate was 64.3%(18/28).Mean KPS was increased from 75.5 at baseline to 87.7 after chemotherapy(P<0.01);Lung cancer symptom scale(LCSS) scores of cough,hemoptysis,chest pain and dyspena were increased at baseline from 64,65,62 and 65 to 90,92,87 and 88,respectively(P<0.01).The median time to progression(TTP) was 5.3 months;Median survival time(MST) was 8.5 months.The main toxicities were fatigue,leucopenia and decrease of hemoglobin with well toleratance.Conclusion:The weekly dose doctaxale is a feasible,well-tolerated,and active scheme in the treatment of elderly patients with advanced NSCLC